|
Mirvetuximab Soravtansine Clinical Trials
4 actively recruiting trials across 3 locations
Also known as: ELAHERE™, IMGN853, MIRV
Pipeline
Phase 2: 4
Top Sponsors
- AbbVie4
Indications
- Cancer4
- Platinum Resistant1
- High Folate Receptor-Alpha Expression1
- Advanced High-Grade Epithelial Ovarian1
- Folate Receptor-Alpha Positive1
Other1 trial
Birmingham, Alabama1 trial
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
University of Alabama at Birmingham (UAB) Hospital /ID# 274793
Phase 2
Los Angeles, California1 trial
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
University of California Los Angeles /ID# 269339
Phase 2
Sarasota, Florida1 trial
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
First Physicians Group /ID# 272180
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.